4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc.

Key Points

• BlackRock acquired 4.25 million Zymeworks shares worth approximately $111.1 million, giving it a 5.82% stake. Institutional investors collectively own 92.89% of the company.
• The FDA expanded approval of Ziihera for first-line treatment of HER2-positive advanced gastroesophageal cancer, potentially broadening Zymeworks’ commercial opportunity and improving its long-term revenue outlook.
• Analyst sentiment is generally positive, with nine Buy ratings and a consensus “Moderate Buy” rating, although Zymeworks recently missed quarterly earnings and revenue estimates and reported a sharp year-over-year revenue decline.

BlackRock Inc. bought a new position in shares of Zymeworks Inc. (NASDAQ:ZYME - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 4,251,030 shares of the company's stock, valued at approximately $111,122,000. BlackRock Inc. owned approximately 5.82% of Zymeworks at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Deutsche Bank AG purchased a new position in shares of Zymeworks in the 2nd quarter valued at $10,383,000. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Zymeworks during the 4th quarter worth $2,338,000. Rubric Capital Management LP boosted its position in Zymeworks by 21.7% during the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company's stock valued at $175,280,000 after purchasing an additional 1,250,000 shares in the last quarter. Bank of America Corp DE boosted its position in Zymeworks by 164.5% during the first quarter. Bank of America Corp DE now owns 236,754 shares of the company's stock valued at $5,928,000 after purchasing an additional 147,230 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Zymeworks by 8.1% in the fourth quarter. Vanguard Group Inc. now owns 2,328,727 shares of the company's stock valued at $61,315,000 after purchasing an additional 174,293 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company's stock.

Trending Headlines about Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Ziihera (zanidatamab-hrii), both with and without tislelizumab plus chemotherapy, for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma. The expanded approval broadens Zymeworks’ commercial opportunity and could improve the long-term revenue outlook for its lead product. FDA approves Ziihera for first-line HER2-positive advanced gastroesophageal cancer
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $55 price target while sharply raising its earnings outlook. Its FY2026 EPS estimate increased to $1.51 from $0.31, and its FY2027 estimate moved to $1.32 from a prior loss estimate of $1.72 per share. The firm also raised several quarterly forecasts, signaling greater confidence in Ziihera-related earnings potential. HC Wainwright raises Zymeworks earnings estimates
• Positive Sentiment: Citigroup reportedly forecast substantial price appreciation, while Citizens JMP assigned Zymeworks a market outperform rating. These calls add further analyst support following the FDA decision. Citigroup forecasts strong price appreciation for Zymeworks Citizens JMP rates Zymeworks market outperform
• Neutral Sentiment: The immediate catalyst is primarily regulatory and expectations-driven; investors will likely look for prescription growth, launch execution and evidence that the approval translates into sustainable revenue and earnings.

Analyst Upgrades and Downgrades

ZYME has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft set a $32.00 price objective on Zymeworks in a research report on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zymeworks in a research note on Friday, July 17th. Wells Fargo & Company boosted their price target on Zymeworks from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Stifel Nicolaus set a $46.00 price objective on shares of Zymeworks in a report on Friday, August 7th. Finally, HC Wainwright increased their price objective on shares of Zymeworks from $51.00 to $55.00 and gave the company a "buy" rating in a research report on Wednesday. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $40.00.

Zymeworks Stock Down 2.6%

Zymeworks stock opened at $28.27 on Friday. The stock has a 50-day moving average price of $24.95 and a 200 day moving average price of $24.84. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -14.00 and a beta of 1.15. Zymeworks Inc. has a 52 week low of $13.60 and a 52 week high of $30.62.

Zymeworks (NASDAQ:ZYME - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Zymeworks had a negative net margin of 405.31% and a negative return on equity of 72.30%. The business had revenue of $3.23 million for the quarter, compared to analyst estimates of $4.54 million. During the same quarter in the previous year, the firm posted $0.03 earnings per share. The business's revenue was down 90.6% on a year-over-year basis. Research analysts anticipate that Zymeworks Inc. will post 1.37 EPS for the current fiscal year.

Zymeworks declared that its board has authorized a share repurchase plan on Thursday, May 14th that permits the company to repurchase $125.00 million in shares. This repurchase authorization permits the company to buy up to 7% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.

Zymeworks Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks' innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source